Viatris boosts pain drug portfolio with $1.7B buyout of Pacira
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.